TGFβ as a therapeutic target in cystic fibrosis

Area of Science:

• Pulmonary Medicine
• Genetics
• Immunology

Background:

• Cystic fibrosis (CF) is a progressive genetic lung disease.
• Current CF therapies often manage secondary complications, not the root causes of airway remodeling and infection susceptibility.
• Transforming growth factor beta (TGFβ) is implicated in fibrosis, inflammation, and injury response, and is a known genetic modifier and biomarker in CF lung disease.

Purpose of the Study:

• To review the pathogenesis of CF lung disease, focusing on potential links to TGFβ signaling.
• To examine the role of TGFβ signaling in lung health and disease.
• To highlight recent research on TGFβ's effects in CF airway epithelial cells and discuss potential TGFβ-targeted therapies for CF.

Main Methods:

• Literature review of studies on CF lung disease pathogenesis.
• Analysis of TGFβ signaling pathways in lung health and disease.
• Review of recent experimental findings in CF airway epithelial cells.
• Overview of potential therapeutic strategies targeting TGFβ in CF.

Main Results:

• TGFβ signaling is extensively involved in cellular processes relevant to both homeostasis and disease.
• The precise mechanisms of TGFβ's effects in CF are not yet fully understood.
• Targeting TGFβ for CF therapy presents both opportunities and challenges.

Conclusions:

• The multifaceted role of TGFβ signaling in CF presents challenges for developing targeted therapeutics.
• Identifying appropriate patient populations and optimal treatment timing are critical considerations for TGFβ-targeted therapies.
• Further research is needed to advance TGFβ-focused therapeutic strategies for cystic fibrosis.